Company intelligence / Profile preview
Immuneering Corporation
United Statesimmuneering.com ↗
- Ownership
- Public · IMRX
- Employees
- ~66
- Development stage
- Other
01
Overview
Immuneering's lead product candidate IMM-1-104 is in Phase 1/2a clinical trials for advanced solid tumors including pancreatic cancer. The FDA has granted Fast Track designation for IMM-1-104 for NRAS-mutant melanoma. Their second candidate IMM-6-415 is also in Phase 1/2a trials for advanced solid tumors with RAS or RAF mutations.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesOral therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Strategic collaborations with top-tier pharmaceutical companies
04
Financials
- Market cap
- $218.3M
- Total revenue
- $0
- Enterprise value
- $76.4M
Beyond the preview
Go deeper on Immuneering Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immuneering Corporation.